七月 2026
- Home
- Alpha Tau Medical
七月 2026的Alpha Tau Medical市场份额分析
Alpha Tau Medical provides highly potent and conformal Alpha Radiotherapy (Alpha DaRT) for solid cancer tumors.
Alpha Tau Medical(包含公司地区分支机构)
查看更多网站流量和参与度信息- alphatau.com
Alpha Tau Medical收入截至 七月 2026为 25M - 50M
Alpha Tau Medical主要域名产生的收入
3 年中Alpha Tau Medical主要域名的收入
Alpha Tau Medical主要域名的收入
Alpha Tau Medical热门域名的总访问量
了解Alpha Tau Medical市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Alpha Tau Medical热门域名的平均访问时长
分析Alpha Tau Medical参与度指标。
过去 3 个月的平均访问时长
子公司明细
Alpha Tau Medical热门域名的平均页面浏览量
了解Alpha Tau Medical如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Alpha Tau Medical 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Alpha Tau Medical Ltd. is developing Alpha DaRT on Jun 3rd '26.June 3, 2026 - Alpha Tau Medical Ltd. and Tolmar International Ltd. have announced a strategic collaboration agreement to develop and commercialize Alpha DaRT for treating prostate cancer in the United States.
六月 4, 2026阅读更多
新闻Alpha Tau Medical Ltd. partnered with TOLMAR Inc. on Jun 3rd '26.Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT(R) Therapy to U.S. Urological Cancer Patients
六月 1, 2026阅读更多
新闻Alpha Tau Medical Ltd. attended event AHNS 12th International Conference on Head and Neck Cancer on Jul 1st '26.Alpha Tau Medical Ltd. reported that an abstract from its clinical trial combining its Alpha DaRT intratumoral alpha-radiation therapy with pembrolizumab in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma has been accepted for a podium presentation at the AHNS 12th International Conference on Head and Neck Cancer in Boston in July 2026.
五月 5, 2026阅读更多
查看 Alpha Tau Medical 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
